Copyright
©The Author(s) 2024.
World J Hepatol. May 27, 2024; 16(5): 822-831
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.822
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.822
Patients with increased presepsin level | Patients with normal presepsin level | P value | |
Age, yr | 49 (43-59) | 52 (42-56) | 0.868 |
Body mass index, kg/m2 | 25.9 (24.7-30.1) | 25.3 (21.6-28.4) | 0.275 |
Male/female | 12/15 | 7/14 | 0.316 |
Etiology of cirrhosis: Alcohol | 13 (48.1) | 10 (47.6) | > 0.050 |
HBV | 3 (11.1) | - | |
HCV | 3 (11.1) | 3 (14.3) | |
Metabolic dysfunction-associated steatotic liver disease | 2 (7.4) | 1 (4.8) | |
Mixed | 4 (14.8) | 3 (14.3) | |
Cryptogenic | 2 (7.4) | 4 (18.0) | |
Child–Pugh score | 9 (8-10) | 8 (7-9) | 0.009 |
Esophageal varices (Grade 1) | 9 (33.3) | 9 (42.9) | 0.353 |
Esophageal varices (Grade 2-3) | 15 (55.5) | 10 (47.6) | 0.399 |
Minimal hepatic encephalopathy | 19 (70.4) | 14 (66.7) | 0.588 |
Overt hepatic encephalopathy | 1 (3.7) | 3 (14.3) | 0.215 |
Ascites | 21 (77.7) | 16 (76.2) | 0.582 |
Ascites (Grade 1) | 11 (40.7) | 12 (57.1) | 0.201 |
Ascites (Grade 2-3) | 10 (37.0) | 4 (19.0) | 0.149 |
Serum total protein, g/L | 73 (65-76) | 70 (61-74) | 0.344 |
Serum albumin, g/L | 32 (30-34) | 35 (33-37) | 0.049 |
Serum total bilirubin, μmol/L | 60 (36-78) | 37 (26-57) | 0.022 |
International normalized ratio | 1.63 (1.39-1.75) | 1.48 (1.36-1.61) | 0.151 |
Red blood cells, 1012 cell/L | 3.6 (3.1-4.2) | 3.6 (3.3-4.2) | 0.934 |
White blood cells, 109 cell/L | 3.7 (2.6-5.2) | 3.3 (2.6-5.9) | 0.942 |
Platelets, 109 cell/L | 94 (52-104) | 94 (66-105) | 0.64 |
Serum creatinine, μmol/L | 77 (67-91) | 76 (66-107) | 0.625 |
Serum sodium, mmol/L | 141 (139-142) | 141 (140-142) | 0.983 |
Alanine aminotransferase, U/L | 26 (18-50) | 28 (20-45) | 0.723 |
Aspartate aminotransferase, U/L | 52 (41-77) | 48 (28-51) | 0.151 |
Gamma glutamyl transferase, U/L | 72 (44-114) | 68 (37-269) | 0.575 |
Alkaline phosphatase, U/L | 261 (194-330) | 242 (215-388) | 0.506 |
C-reactive protein, mg/L | 9 (5-15) | 7 (3-12) | 0.399 |
Splenic length, cm | 15.0 (13.0-17.0) | 15.0 (13.2-18.4) | 0.708 |
Direct correlations | Inverse correlations | ||||
Taxon rank | Taxon | R, P value | Taxon rank | Taxon | R, P value |
Phylum | Proteobacteria | 0.316, 0.029 | Family | Lachnospiraceae | 0.447, 0.0421 |
Class | Bacilli | 0.470, 0.0321 | Propionibacteriaceae | -0.302, 0.038 | |
Gammaproteobacteria | 0.351, 0.014 | Genus | Fusicatenibacter | -0.297, 0.040 | |
Family | Erysipelatoclostridiaceae | 0.384, 0.007 | Holdemanella | -0.315, 0.029 | |
Eubacteriaceae | 0.340, 0.018 | ||||
Vibrionaceae | 0.366, 0.010 | ||||
Xanthobacteraceae | 0.363, 0.011 | ||||
Genus | Escherichia-Shigella | 0.338, 0.019 | |||
Stenotrophomonas | 0.365, 0.011 | ||||
Vibrio | 0.346, 0.016 |
Elevated baseline presensin level (n = 13) | Normal baseline presensin level (n = 9) | |||||
At the beginning of the study | After the probiotic course | P value | At the beginning of the study | After the probiotic course | P value | |
Child–Pugh score | 9 (8-11) | 7 (6-9) | 0.004 | 8 (7-8) | 7 (6-8) | 0.124 |
Child–Pugh class, A/B+C | 0/13 | 5/8 | 0.020 | 0/9 | 2/7 | 0.235 |
No hepatic encephalopathy | 2 (15.4) | 8 (61.5) | 0.021 | 2 (22.2) | 3 (33.3) | 0.500 |
Ascites | 12 (92.3) | 5 (38.4) | 0.006 | 8 (88.9) | 5 (55.5) | 0.147 |
Serum albumin, g/L | 32 (30-34) | 33 (32-39) | 0.033 | 35 (33-36) | 38 (37-39) | 0.008 |
Serum total bilirubin, μmol/L | 52 (36-120) | 29 (26-40) | 0.016 | 34 (26-44) | 25 (22-35) | 0.066 |
Alanine aminotransferase, U/L | 26 (18-47) | 26 (18-40) | 0.272 | 30 (21-41) | 33 (25-39) | 0.813 |
Aspartate aminotransferase, U/L | 60 (37-75) | 39 (27-51) | 0.012 | 45 (28-51) | 36 (36-42) | 0.314 |
Gamma glutamyl transferase, U/L | 92 (44-207) | 56 (40-89) | 0.196 | 37 (31-317) | 62 (30-115) | 0.193 |
Alkaline phosphatase, U/L | 268 (245-355) | 210 (187-245) | 0.013 | 261 (227-446) | 215 (188-275) | 0.110 |
- Citation: Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G, Fedorova M, Romanikhin F, Zharkova M, Zolnikova O, Bagieva G, Ivashkin V. Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis. World J Hepatol 2024; 16(5): 822-831
- URL: https://www.wjgnet.com/1948-5182/full/v16/i5/822.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i5.822